Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
Pharmaceutical Statistics|August 23, 2025
The Estimand Framework and Causal Inference: Complementary Not Competing ParadigmsThomas Drury, Jonathan W Bartlett, David Wright, et al.BMC Medicine|July 27, 2023
Why estimands are needed to define treatment effects in clinical trialsOliver N Keene, Helle Lynggaard, Stefan Englert, et al.Pharmaceutical Statistics|January 21, 2021
Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowingNicky Best, Robert G Price, Isabelle J Pouliquen, et al.Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 12, 2019
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthmaSteven W Yancey, Hector G Ortega, Oliver N Keene, et al.Pharmaceutical Statistics|January 19, 2007
Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN studyOliver N Keene, Mark R K Jones, Peter W Lane, et al.Pharmaceutical Statistics|June 17, 2014
Missing data sensitivity analysis for recurrent event data using controlled imputationOliver N Keene, James H Roger, Benjamin F Hartley, et al.Pharmaceutical Statistics|January 8, 2022
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatmentBenjamin Hartley, Thomas Drury, Sally Lettis, et al.Pharmaceutical Statistics|November 9, 2018
Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatmentJames H Roger, Daniel J Bratton, Bhabita Mayer, et al.Pharmaceutical Statistics|January 11, 2020
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPDOliver N Keene, Stephen Ruberg, Alexander Schacht, et al.Pageof 4